Roche gains positive CHMP opinion for Actemra / RoActemra in giant cell arteritis

Roche announced today that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of Actemra ®/RoActemra® (tocilizumab) for the treatment of giant cell arteritis (GCA), a chronic and potentially life-threatening autoimmune condition.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news